Anavex Life Sciences Corp (AVXL)

[nidan7500]

Steady _T

In fact there are a number of ways that the S1 receptor can be agonized and it appears that each different way has different results to a greater or lessor degree. There are agonists that doc at the "normal" docking site and agonize S1. There are agonists that are allosteric agonists that activate the S1 receptor by docking at a different part of the S1 receptor molecule. Apparently there are a number of different allosteric docking sites.
This is complicated stuff and it is not well understood.]

These are exactly the kinds of thought processes that should have been explored over the past 30+ years , but were not. Maybe now they will be analyzed. It's obvious the science-medical -regulatory community just does not get the whole CNS diseases discovery process. Would like to see AVXL take charge of the links here and kick some BP axx.